China Factory Activity Extends Growth in April Despite Global Pressures 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Asian Stock Markets Rise Amid Wall Street Rally and U.S.-Iran Tensions 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Oil Prices Ease but Remain Set for Strong April Gains Amid Middle East Tensions 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears 
US Dollar Weakens as Yen Surges Amid Japan Intervention and Central Bank Moves 
Panama Defends Port Takeover Amid U.S.-China Tensions and Canal Dispute 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
AI Stocks Rally in Asia as Oil Surge and Hawkish Central Banks Shake Global Markets 
Wall Street Mixed as Apple Earnings Boost Nasdaq and Oil Prices Ease 
Gold Prices Dip Ahead of Fed Decision Amid Rising Middle East Tensions 
Gold Prices Slip Amid Iran Tensions and Rising Rate Concerns 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Samsung Biologics Co. is adding a new plant to its portfolio, and it will be its fifth facility for Contract Development and Manufacturing Organization (CDMO) deals. The South Korean biotech firm is building its newest plant in Songdo, Incheon, where it is currently headquartered.
According to The Korea Economic Daily, once Samsung Biologics completes the construction of the CDMO factory, its total production capacity will increase to 800,000 liters per year. The company is investing KRW1 trillion or $762.2 million for this project in South Korea.
It was noted that the company is making a fast follow-up with its investment since the fourth plant is also under construction. This factory has been dubbed the largest single biomanufacturing facility in the world, and construction is currently in full swing.
Samsung Group’s biotech arm confirmed the construction of its new Songdo plant late last week during its board meeting. It will soon rise on the second bio campus in the region’s free economic zone located west of Seoul. Prior to this announcement, Samsung Biologics already said in July of last year that it would allot KRW7.5 trillion to set up the campus by the year 2032.
In any case, the fifth plant will be the first one to be constructed on the second bio campus. While the third plant was built with just a KRW850 trillion budget, it is said to have a similar production capacity as the fifth factory. Sources said that the latest facility costs more because it will be constructed on a greenfield.
Korea Joongang Daily reported that Samsung Biologics would break ground for its fifth plant soon, and it is expected to be completed by September 2025. It will sit on a 96,000 square meter lot inside the Bio Campus II.
The company is expanding to take advantage of the current steady growth in demand for medical treatments. Finally, Samsung Biologics is taking this aggressive step of further building up its production facilities to cement its leadership in the global CDMO market.
“Amid the steady global demands for biopharmaceuticals, outsourcing of biomedical products is on the rise since the Covid-19 outbreak,” John Rim, Samsung Biologics’ chief executive officer, commented. “Preemptive investment is needed in order to continue our leadership in the market after the fourth plant.”
